Citations

Clear

4207 citation(s) found for "Chen, Yu".

OCT-Based Differentiation of First Acute Optic Neuritis
Pakeerathan, Thivya , Davis, James , Sotirchos, Elias S. , Said, Yana , Havla, Joachim , Ringelstein, Marius, Aktas, Orhan, Weise, Margit, Gernert, Jonathan A. , Bsteh, Gabriel , Rommer, Paulus , Pröbstel, Anne-Katrin, Kulsvehagen, Laila , Pretzsch, Roxanne , Schoenholzer, Kean , Padungkiatsagul, Tanyatuth , Moss, Heather E. , Navarro, Sylvia E. Villarreal , Herwerth, Marina , Graure, Madalina, Kana, Veronika , Stiebel-Kalish, Hadas, Zlatkin, Rita , Arnold, Anthony C. , Bonelli, Laura , Stellmann, Jan-Patrick, Stolowy, Natacha , Schneider-Gold, Christiane, Kümpfel, Tania, Philipp, A, Pittock, S., Ayzenberg, I., Henderson, Amanda D , Sotirchos, Elias S , Said, Yana , Havla, Joachim , Ringelstein, Marius , Aktas, Orhan , Gernert, Jonathan A , Kornek, Barbara , Bsteh, Gabriel , Rommer, Paulus S , Krajnc, Nik , Pröbstel, Anne-Katrin , Papadopoulou, Athina , Kulsvehagen, Laila , Pretzsch, Roxanne , Schoenholzer, Kean , Padungkiatsagul, Tanyatuth , Moss, Heather E , Villarreal Navarro, Sylvia E , Herwerth, Marina , Graure, Madalina , Kana, Veronika , Stiebel-Kalish, Hadas , Arnold, Anthony C , Bonelli, Laura , Stellmann, Jan-Patrick , Stolowy, Natacha , Schwake, Carolin , Schneider-Gold, Christiane , Kuempfel, Tania , Albrecht, Philipp , Rattanathamsakul, Natthapon , Pittock, S J , Flanagan, E P , Carta, Sara , Mariotto, Sara , Gold, Ralf , Chen, John J , Ayzenberg, Ilya , Henderson, Amanda D. , Ringelstein, Marius , Aktaş, Orhan , Stiebel‐Kalish, Hadas , Kümpfel, Tania , Rattanathamsakul, Natthapon , Pittock, Sean J. , Flanagan, Eoin P. , Carta, Sara , Mariotto, Sara , Chen, John J. , Ayzenberg, Ilya

Mayo Clinic

Neurology Neuroimmunology & Neuroinflammation | January 7, 2026 | Volume: 13 | Issue: 2 | Pages: No page available

10.1212/nxi.0000000000200531 | PMID 41499724 Get It

Transforming nephrology through artificial intelligence: a state-of-the-art roadmap for clinical integration
Cheungpasitporn, W., Athavale, Ambarish M., Ghazi, Lama , Kashani, Kianoush B, Colicchio, Tiago K. , Koyner, Jay L. , Chen, Jin , Ix, Joachim H, Nadkarni, Girish N. , Neyra, Javier A., Kashani, Kianoush , Cheungpasitporn, Wisit , Kashani, Kianoush B , Colicchio, Tiago , Neyra, Javier A , Koyner, Jay L , Ghazi, Lama , Cheungpasitporn, Wisit , Ix, Joachim H. , Neyra, Javier A.

Mayo Clinic

Clinical Kidney Journal | January 7, 2026 | Volume: 19 | Issue: 2 | Pages: No page available

10.1093/ckj/sfag004 | PMID 41704427 Get It

ABSTRACT Artificial intelligence (AI), encompassing machine learning, deep learning and generative AI, is poised to redefine nephrology by enabling earlier detection, more precise risk stratification and workflow-integrated clinical decision support across the spectrum of kidney disease. This state-of-the-art review synthesizes emerging applications of AI in acute kidney injury (AKI), chronic kidney disease (CKD), dialysis and kidney transplantation, with attention to clinical integration, real-world validation, workflow implementation and translational challenges. In AKI, predictive models trained on high-frequency electronic health record data and intensive care unit telemetry have demonstrated strong performance in forecasting critical events, yet translation into routine clinical workflows remains limited. In CKD, machine learning tools support progression risk stratification and phenotype clustering, with the potential to inform individualized surveillance and therapy. AI-enabled dialysis management systems optimize ultrafiltration, anemia control and vascular access surveillance, while generative AI and large language models offer novel capabilities for clinical documentation, triage and patient education. In transplantation, AI applications span organ allocation, dynamic graft monitoring and digital pathology-assisted rejection classification, with validated tools such as the iBox system gaining regulatory recognition. Implementation challenges include data heterogeneity, bias, interpretability, regulatory uncertainty and workflow integration. Looking ahead, multimodal integration of imaging, pathology and multi-omics data may support biologically informed precision nephrology. Reinforcement learning, digital twins and ambient intelligence are emerging as adaptive decision-support paradigms rather than autonomous care systems. Regulatory frameworks are evolving to accommodate adaptive algorithms, underscoring the need for clinician engagement in model development, validation and deployment. As AI matures from pilot to practice, nephrologists who embrace and help shape these tools will lead the transition toward a more personalized, efficient and equitable future for kidney care.
Relapse and Emergent Resistance With Novel Short-Course Regimens for Multidrug-Resistant Tuberculosis, United States, 2022–2024
Liang, Rina , Brust, James C. M. , Reed, Caitlin , Escuyer, Vincent , Armstrong, Derek T. , Parrish, Nicole , Valois, Patrick , Rowlinson, Marie‐Claire , Marinova‐Petkova, Atanaska, Bisson, Gregory P., Labuda, Sarah M. , Colon-Semidey, Angel, Haley, Connie A. , Ashkin, David , Lardizabal, Alfred , PATRAWALLA, AMEE S, Cuenca, Alice, Haas, Michelle, Brostrom, Richard, Mbakwem, Chima, Schechter, Marcos C, Ray, Susan M, Cummins, Jason, Cahill, Barbara, Arn, Katherine, Chen, Lisa , Wilson, John W, Goswami, Neela D. , Peloquin, Charles A , Lardizabal, Alfred , Haas, Michelle K , Schechter, Marcos C , Ray, Susan M , Cummins, Jason , Cahill, Barbara , Goswami, Neela D , Colón‐Semidey, Angel, Peloquin, Charles A. , Arn, Katherine

Mayo Clinic

Open Forum Infectious Diseases | January 6, 2026 | Volume: 13 | Issue: 1 | Pages: No page available

10.1093/ofid/ofaf786 | PMID 41541397 Get It

Abstract Background Bedaquiline, pretomanid, and linezolid with or without moxifloxacin (BPaL/M) are recommended oral 6-month treatment regimens for multidrug- or rifampin-resistant (MDR/RR) tuberculosis (TB). Since the US rollout of these regimens in 2019, the US Centers for Disease Control and Prevention (CDC) and partners have identified patients who failed or relapsed on these regimens. Methods Here, we report a case series of US patients with TB treated with BPaL/M-containing regimens, who experienced adverse outcomes during the period 2022‒2024, including drug resistance, relapse, and treatment failure. Results Clinical and public health outcomes were significant for US patients reported. There were 8 patients identified (n = 8). 5 (62.5%) were male, with a median age 57 years, 2 (25%) were previously treated for TB, and 8 (100%) presented with cavitary disease. This included a patient who died from infectious TB with acquired resistance after exposing over 100 healthcare workers, a waitress who was found to have highly infectious TB at the time of her relapse, and a son who contracted Mycobacterium tuberculosis (Mtb) with reduced activity to bedaquiline from his mother in a household transmission event. Conclusions These patients highlight consequences, both for the individual and public health, of relapse and treatment failure in real-life operational settings that may not be readily evident in well-controlled and well-resourced clinical trials. Despite the advent of shorter and better tolerated bedaquiline-based regimens, US clinicians continue to face challenges in managing drug-resistant TB. These data support the need for expert management of these patients beyond routine TB care, as well as the need for close monitoring and follow-up months after treatment completion.
Living liver donor safety: Intraoperative considerations in living liver donation—Guidelines from the ILTS–iLDLT group consensus conference 2025
Bhangui, Prashant , Hakeem, Abdul Rahman , Maira, Tommaso Di , Rammohan, Ashwin, Sayed, Blayne A. , Soejima, Yuji , Shingina, Alexandra , Cheah, Yee Lee , McCluskey, Stuart, Spiro, Michael , Ganesh, Swaytha , Rajalingam, Rajesh , Gupta, Subash , Findlay, James Y. , Chieh, Alfred Kow Wei, Sakamoto, Seisuko, Xia, Qiang, Kim, Ki-Hun , Polak, W., Soin, A G, Pomposelli, James J. , Vyas, Mary, Wiggins, Chantal, Mas, Valeria, Taner, Timucin, Broering, Dieter, Chen, Chao-Leng, Burra, Patrizia, Ascher, N. L., Lerut, Jan, Rela, Mohamed, Selzner, Nazia, Balci, Deniz, Olthoff, Kim M. , Polak, Wojciech G. , Hakeem, Abdul , Rammohan, Ashwin , Sayed, Blayne A , McCluskey, Stuart , Findlay, James, Sakamoto, Seisuko , Xia, Qiang , Polak, Wojciech G , Sapisochin, Gonzalo , Pomposelli, James , Selzner, Nazia , Balci, Deniz , Bhangui, Prashant , Di Maira, Tommaso , Gupta, Amar C. , Xia, Qiang , Sapisochín, Gonzalo , Soin, Arvinder S., Taner, Timuçin , Bröering, Dieter C. , Terrault, Norah A. , Burra, Patrizia , Hirschfield, Gideon M. , Lerut, Jan , Rela, Mohamed , Heimbach, Julie K. , Selzner, Nazia

Mayo Clinic

Liver Transplantation | January 5, 2026 | Volume: 32 | Issue: 4 | Pages: 592-608

10.1097/lvt.0000000000000800 | PMID 41490582 Get It

The success of living donor liver transplantation (LDLT) has bridged the growing gap between organ demand and availability in patients with liver failure or liver cancer. Safety of the living liver donor (LLD) is paramount, and astute intraoperative management plays a critical role in ensuring optimal outcomes for them. Given that intraoperative surgical and anesthesia practices vary widely across centers, the International Liver Transplantation Society (ILTS) and the International Living Donor Liver Transplantation Group (iLDLT Group) convened a global consensus conference in Toronto in March 2025 to develop guidelines for intraoperative management of the LLD. This manuscript details the recommendations on intraoperative considerations for the safety of LLD developed by Working Group II of the Consensus Scientific Committee, using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system for assessment of recommendations, and the Danish model of consensus. Working Group II focused on intraoperative monitoring, fluid and ventilation strategies, surgical techniques for vascular and biliary division, surgeon and center-specific experience, and intraoperative crises planning. These guidelines aim to support both established and emerging LDLT teams to ensure high-quality and safe intraoperative care for the LLD.
Physeal Allograft Transfer for Physeal Bars: A Safety and Feasibility Study in a Domestic Swine Model
Korpershoek, J. V., Chen, C., Nagelli, C. V., Lydon, K. L., Floren, M. L., Saris, D. B. F., Larson, A. N., Milbrandt, T. A., Korpershoek, Jasmijn V. , Chen, Chun‐Ho , Korpershoek, Jasmijn V , Chen, Chunho , Nagelli, Christopher V. , Lydon, Katherine L. , Floren, Michael L. , Saris, Daniël B.F.

Mayo Clinic

Journal of Orthopaedic Research | January 4, 2026 | Volume: 44 | Issue: 1 | Pages: No page available

10.1002/jor.70133 | PMID 41485130 Get It

ABSTRACT Premature physeal closure occurs following trauma, cancer, or infection. Current treatments have poor success rates. With recent pediatric donor tissue availability, physeal allograft transfer (PAT) can now be considered. The purpose of this study was to study the safety and feasibility of PAT in a large animal model. The aim of this study is to gather foundational data to inform future studies into the efficacy of PAT. Physeal defects were created in the distal femur of nine female domestic swine and treated with PAT from two male donor pigs, cementation, or bone autograft. Viability was assessed. After 3 months, physes were visualized using CT and MRI. Integration, tissue composition, donor DNA presence, and microscopic appearance were evaluated. Physeal allografts demonstrated 93% viability after procurement and preservation. All animals reached the 3‐months study endpoint without gross deformations. No physeal bars formed in any group. Cystic changes were seen in experimental and control femurs. All groups showed disorganized tissue architecture without growth plate recapitulation. High allografts viability and structural integrity after procurement support the potential of this treatment. Although no gross deformities were found, transferred physes demonstrate poor integration and incomplete repair. The lack of physeal bar formation in the control group limits the reliability of the animal model for studying physeal allograft transfer. Lastly, this study was designed as a feasibility study and lacks power to compare treatment effects statistically. The efficacy of PAT for preventing growth arrest remains undetermined.
Reduced Preparatory Responses in People with Dementia Predict Caregiver Mental Health Improvements After Care Ends
Scheffer, Julian A. , Chen, K., Lwi, Sandy J. , Chen, Enna , Merrilees, Jennifer , Levenson, Robert, Yee, Claire , Wells, Jenna L. , Levenson, Robert W.

Mayo Clinic

Innovation in Aging | January 3, 2026 | Volume: 9 | Issue: Supplement_2 | Pages: No page available

10.1093/geroni/igaf122.1644 Get It

Abstract Caregivers for people with neurodegenerative disease (PWNDs) often experience mental and physical health problems, especially when caring for PWNDs who have deficits in emotional functioning. We studied 65 PWNDs and their caregivers both during active caregiving and after caregiving had ended to determine: (a) how caregiver health changes after caregiving ends; and (b) whether PWNDs’ emotional functioning predicts these changes. PWND emotional functioning was assessed in the laboratory by measuring their generation of preparatory physiological activity (e.g., increased heart rate) to an upcoming emotional event (i.e., emotion eliciting films). Caregiver mental and physical health were measured using the Short-Form Health Survey (SF36) during active caregiving and again after caregiving had ended. Results indicated that, overall, caregivers reported increases in mental health, (t(36) = 2.58, p = .014, 95% CI [1.31, 10.93]) but decreases in physical health (t(36) = -2.35, p = .025, 95% CI [-7.26, -0.53]) across the two measurement periods. Using latent change score models, PWNDs’ preparatory physiological response impairments were associated with better caregiver mental health trajectories (β = -0.37, SE = 0.04, p = .003) such that smaller PWND preparatory responses predicted greater improvements in caregiver mental health (β = 9.92, SE = 2.84, p < .001). There was no association with changes in caregiver physical health. Smaller preparatory physiological responses in PWNDs may indicate diminished emotional responding, which is linked with lower caregiver mental health during active caregiving. Once caregiving ends, these caregivers may be most likely to “rebound” and show improvements in mental health.
Topical Issues for the Future of Radiation Protection
Nelson, Kevin, Czarwinski, Renate , Wilson, Charles , LeGuen, Bernard, Chen, Jing, Vandenhove, Hildegarde Annie, Niu, Shengli, Damilakis, John , Bryant, Peter Alfred, Kevin, Nelson, Vandenhove, Hildegarde , Niu, Shengli, Schneider, Thierry

Mayo Clinic

Health Physics | January 2, 2026 | Volume: 130 | Issue: 2 | Pages: 137-144

10.1097/hp.0000000000002107 | PMID 41481178 Get It

This paper summarizes the presentations and panel discussion provided at Plenary Panel #2 on the first day of the 16 th World Congress of the International Radiation Protection Association (IRPA) jointly organized with the 69th Annual Meeting of the Health Physics Society (HPS) in Orlando/Florida in July 2024. International organizations that play a key role in radiation protection and are close in contact with IRPA by official agreements or even MoU’s (Memorandum of Understanding) presented highlights of their projects in radiation protection as well as results. Topical issues on their current work program as seen in a list of statements, including future efforts, were presented and discussed. The needs of practitioners were stressed for recognition by the representatives of the international organizations to be included in their projects. Requested and presented topics were: • Key challenges for radiation protection practitioners in the next 10 y. • Potential effects of emerging science on radiation protection. • Challenges for implementation of IAEA Safety Standards in low- and middle-income countries. • Challenges in occupational radiation protection. • Broadening the process of optimization. • Impact of emerging technologies on radiation protection. • Ensuring radiation protection workforce for the future.
Kinetics of hematologic response in AL amyloidosis: Insights from clinical and cytogenetic subgroup analysis in the daratumumab era
Bazarbachi, Abdul‐Hamid , Zanwar, Saurabh , Trajanova, Despina, Gertz, Morie A., Dispenzieri, Angela, Kumar, Shaji, D'Souza, A, Patwari, Anannya , Cowan, Andrew, Chen, GuiZhen, Milani, P. , Palladini, Giovanni, Bodanapu, Geethika , Mohty, M, Lentzsch, Suzanne , Muchtar, E., Bazarbachi, Abdul Hamid , Chakraborty, Rajshekhar , Hegenbart, Ute , Bhutani, Divaya , Gertz, Morie A. , Dispenzieri, Angela , D’Souza, Anita , Milani, Paolo, Sanchorawala, Vaishali , Mohty, Mohamad , Schönland, Stefan , Muchtar, Eli , Chakraborty, Rajshekhar

Mayo Clinic

HemaSphere | December 29, 2025 | Volume: 9 | Issue: 12 | Pages: No page available

10.1002/hem3.70276 | PMID 41473002 Get It

Abstract Rapid and profound reduction of free light chains (FLCs) improves outcomes in AL amyloidosis; however, early FLC kinetics with daratumumab‐based frontline therapy remain undefined. We retrospectively analyzed 315 patients treated with daratumumab–bortezomib–cyclophosphamide–dexamethasone (Dara–VCd) or Dara–Vd at eight centers. Involved FLC (iFLC), the difference between iFLC and uninvolved FLC (dFLC), and hematologic response (≥very good partial response [VGPR]) were assessed at baseline and at 1, 3, and 6 months, and correlated with light chain isotype, disease burden (bone‐marrow plasma‐cell percentage [%BMPC], baseline dFLC), and cytogenetics. Hematological ≥VGPR increased from 49.8% at 1 month to 66.0% at 3 months. The kappa isotype showed slower responses, with higher iFLC/dFLC and lower ≥VGPR at each time point compared to lambda. Higher %BMPC or baseline dFLC predicted persistently elevated iFLC/dFLC and reduced ≥VGPR. The t(11;14) translocation was associated with lower baseline FLC but similar subsequent kinetics. BMPC < 10% and dFLC < 18 mg/dL independently predicted early ≥VGPR (in ≤1 month). Early ≥VGPR conferred superior hematologic event‐free survival (heme‐EFS) and overall survival (OS) versus later responders (P < 0.001). At a 3‐month landmark, achieving dFLC < 1 mg/dL further stratified prognosis, conferring longer heme‐EFS and OS (P < 0.01). Frontline Dara‐based therapy elicits rapid, deep responses in AL amyloidosis; early ≥VGPR (within 1 month) and dFLC < 1 mg/dL by 3 months predict durable EFS and OS, whereas higher baseline disease burden delays hematologic response.
Shared TCRs in peripheral blood offer robust celiac disease classification independent of gluten Intake
Elyanow, Rebecca , Marietta, Eric, Bharanikumar, Ramit, Zhou, Wenyu , Chen-Harris, Haiyin, Bhagat, Govind , Green, Peter H., Howie, Bryan, Robins, Harlan , Murray, Joseph A., Bhagat, Govind , Choung, Rok Seon , Chen‐Harris, Haiyin , Green, Peter H., Howie, Bryan, Neuhausen, Susan L. , Murray, Joseph A.

Mayo Clinic

No container title available | December 27, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2025.12.26.696039 Get It

Abstract Background and Aims Celiac disease (CeD) is a chronic digestive autoimmune disorder affecting approximately 1% of the worldwide population. It is driven by T cells activated by specific HLA-DQ2 or HLA-DQ8 molecules leading to the destruction of intestinal villi. We aimed to characterize shared CeD-specific T cells in patients on and off a gluten-free diet (GFD) from a large cohort of cases and controls. Methods We performed bulk TCRβ immune sequencing of the peripheral blood of 1,604 biopsy-confirmed CeD patients (1,339 on GFD, 265 on normal diet) and 1,100 controls. We identified over 300 TCRβs enriched in CeD cases versus controls in an HLA-aware manner, controlling for CeD risk alleles. Results CeD-associated TCRβs were found to be more predictive of disease than previously characterized gliadin and glutenin-binding TCRs in a validation cohort. Furthermore, the clonal breadth of these TCRβs was associated with increased intestinal damage. Immune sequencing of the peripheral blood also uncovered repertoire-level differences between CeD patients and controls. CeD patients displayed significantly higher productive clonality compared to age-matched controls as well as expansion of TCRβs specific to cytomegalovirus (CMV) and Epstein-Barr Virus (EBV). Conclusions These findings underscore the value of unbiased immune repertoire sequencing to identify novel biomarkers for autoimmune disease and to discover new disease mechanisms which can improve both diagnosis and treatment of disease.
SGLT ‐2 Inhibitors Are Associated With Lower Mortality and Decompensation in Patients With MASH Cirrhosis and Type 2 Diabetes
Kim, Do Han , Ko, Donghyun , Chen, Vincent L., Porres, J.A., Alatorre, Carlos, Nieto, Luis M., Argueta, Pedro Palacios , Lukens, F, Kim, Donghee, Karagozian, Raffi, Bansal, Meena B. , Wijarnpreecha, Karn, Kim, Donghee , Nieto, Luis M. , Kim, Do Han , Chen, V L , Palacios Argueta, Pedro , Lukens, Frank J., Kim, Donghee , Ko, Donghyun , Alatorre, Carlos Elizondo, Kröner, Paul T. , Wijarnpreecha, Karn

Mayo Clinic

Liver International | December 27, 2025 | Volume: 46 | Issue: 2 | Pages: No page available

10.1111/liv.70490 | PMID 41454700 Get It

ABSTRACT Introduction Metabolic dysfunction‐associated steatotic liver disease (MASLD) and steatohepatitis (MASH) represent a spectrum of liver conditions that can gradually progress to cirrhosis. Sodium‐glucose co‐transporter‐2 (SGLT‐2) inhibitors have shown benefits in reducing hepatic steatosis and liver‐related events in MASLD. This study aims to assess whether SGLT‐2 inhibitors are associated with a reduced risk of all‐cause mortality and disease‐specific outcomes in patients with MASH cirrhosis and type 2 diabetes (T2D). Methods A retrospective cohort study was performed using TriNetX. Patients with T2D and MASH cirrhosis on SGLT‐2 inhibitors were matched 1:1 with other glucose‐lowering drugs (oGLDs) based on demographics, comorbidities and medications. Primary outcomes included all‐cause mortality, hepatic decompensation and major adverse liver outcomes (MALO). Cox‐proportional hazards models were used to estimate hazard ratios (HRs) with 95% confidence interval (CI). Results A total of 51 427 patients with MASH cirrhosis and T2D were identified, of which 6833 (13.28%) were on SGLT‐2 inhibitors. Patients on SGLT‐2 inhibitors ( n = 6449, mean age 63.7 years, 52.9% female) were matched with 6449 individuals (mean age 63.9 years, 53.5% female) on oGLDs. The SGLT‐2 inhibitors cohort had statistically significantly lower risk of all‐cause mortality (HR: 0.58, 95% CI: 0.53–0.63), hepatic decompensation (HR: 0.85, 95% CI: 0.81–0.90) and MALO (HR: 0.88, 95% CI: 0.83–0.93). Conclusion SGLT‐2 inhibitors are associated with a reduced risk of all‐cause mortality in patients with MASH cirrhosis and T2DM, which may be partly attributable to a lower risk of hepatic decompensation and subsequent events. Further studies are warranted as SGLT‐2 inhibitors may serve as an adjunctive therapy for patients with MASH cirrhosis.